Novo Nordisk A/S Increased Operating Profit by 18 Pct in the First Quarter of 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BAGSVAERD, DENMARK--(Marketwired - May 01, 2013) - Financial report for the period 1 January 2013 to 31 March 2013. Sales growth of 13% driven by Victoza®, NovoRapid® and Levemir

Company announcement No 32 / 2013: http://hugin.info/2013/R/1698229/559879.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1698229]


CONTACTS FOR FURTHER INFORMATION
Media:
Mike Rulis
+45 4442 3573
Email Contact

Ken Inchausti (US)
+1 609 514 8316
Email Contact

Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
Email Contact

Frank Daniel Mersebach
+45 4442 0604
Email Contact

Lars Borup Jacobsen
+45 3075 3479
Email Contact

Jannick Lindegaard
(US) +1 609 786 4575
Email Contact

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC